The abstract is read at the publisher; the summary is JClub's.
In mouse models of alcohol use disorder, experimenter-administered mitragynine (i.p.) inhibits ongoing alcohol consumption and markedly attenuates relapse to binge drinking, including during limited-time access.
- Why it matters: AUD treatments often show modest compliance and efficacy, and tinnitus is an aversive condition that may share unresolved mechanisms with AUD.
- What they did: The study tested mitragynine across multiple mouse AUD symptom models (ongoing drinking, abstinence prophylaxis, relapse/binge, seeking, extinction/re-establishment) and used oral self-administration training to assess compliance.
- The result: Mitragynine reduced alcohol seeking and re-establishment after extinction, showed significant antidepressive effects during alcohol withdrawal, and in a gerbil noise-trauma model reduced tinnitus.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.